A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Standard of Care Plus Vancomycin or Linezolid as Empiric Therapy in Febrile Neutropenic Adults With Cancer

Trial Profile

A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Standard of Care Plus Vancomycin or Linezolid as Empiric Therapy in Febrile Neutropenic Adults With Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Cefepime; Linezolid; Meropenem; Piperacillin/tazobactam; Vancomycin
  • Indications Febrile neutropenia
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 09 Sep 2016 Status changed from not yet recruiting to discontinued as the study is no longer aligned with the revised clinical development plan and commercial strategy
    • 13 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top